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Abstract: Drug delivery systems are used to improve the biopharmaceutical properties of curcumin. 
Our aim was to investigate the effect of a water-soluble ‘two in one’ polymer containing covalently 
bonded PEG and βCD moieties (βCPCD) on the solubility and bioavailability of curcumin and 
compare it to a polymeric β-cyclodextrin (βCDP) cross-linked with epichlorohydrin. Phase-
solubility and dynamic light scattering (DLS) experiments showed that the solubility of curcumin 
increased significantly in 10 m/m % βCPCD and βCDP solutions, but βCPCD–curcumin particles 
had higher hydrodynamic volume. The formation of the βCPCD–curcumin complex in solution and 
sedimented phase was confirmed by NMR spectroscopy. Biocompatibility and permeability 
experiments were performed on Caco-2 cells. Polymers did not show cytotoxicity up to 10 m/m % 
and βCPCD significantly increased the permeability of curcumin. DLS measurements revealed that 
among the interaction of polymers with mucin, βCPCD formed bigger aggregates compared to 
βCDP. Curcumin complexes were lyophilized into capsules and structurally characterized by 
micro-CT spectroscopy. Drug release was tested in a pH 1.2 medium. Lyophilized complexes had a 
solid porous matrix and both βCPCD and βCDP showed rapid drug release. βCPCD provides an 
opportunity to create a swellable, mucoadhesive matrix system for oral drug delivery. 
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1. Introduction 
Covalently linked cyclodextrin-containing macromolecular drug carrier systems 
have been investigated since the 1980s [1]. Several types of these macromolecular systems 
can be distinguished according to their structure such as linear polymers containing 
pendant cyclodextrin (CD) moieties [2], cross-linked cyclodextrin polymers [3,4] or 
polyrotaxanes [5–7]. Epichlorohydrin is a widely used cross-linker for the synthesis of 
cyclodextrin polymers [8], that are used for solubilization and stabilization of water-
insoluble chemical substances [9,10]. Various drug molecules and bioactive agents such 
as doxorubicin and artemisinin [11], glipizide [12], triclosan [13], naproxen [14] and 
paclitaxel [15] were complexed by these water-soluble cyclodextrin polymers for drug 
delivery studies. By manipulating the cross-linking reaction conditions, such as the 
addition rate of cross-linker, reaction temperature and time, soluble or insoluble 
cyclodextrin polymers in water and/or other organic solvents are produced [3,16–19]. 
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Cyclodextrin and polymer binary systems are also used to improve the solubilization 
of poorly soluble drugs [20]. To achieve higher degrees of drug solubilization, the 
synergistic effect of an active pharmaceutical ingredient (API), a cyclodextrin and a water-
soluble polymer in solution was reported [21]. The formed ternary complex gives an 
alternative way for solubilization, especially when a high amount of CD is needed for 
complexation. The interaction of water-soluble polymers with drug molecules may occur 
by means of ion–ion, ion–dipole and dipole–dipole electrostatic bonds, van der Waals 
force, or 3-center or 2-electron bonds [22]. The water solubility and absence of biological 
activity are the most important requirements to choose polymers for complexes [22]. The 
most frequently used polymers for this purpose may be classified as natural, semi-
synthetic and synthetic polymers [22]. The semi-synthetic polymers are carboxymethyl 
cellulose [21,23,24] and hydroxypropyl methylcellulose [25,26]. In several studies, 
povidone, polyvinyl alcohol and polyethylene glycol (PEG) promoted the complexation 
of drugs as a synthetic polymer suitable for ternary complex formation [27–30]. PEG is 
widely used as excipient or adjuvant in a variety of pharmaceutical formulations [31]. 
Nevertheless, CDs can be covalently linked to form polymers. CD polymers containing 
PEG soft units have been used to synthesize drug carrier gels for pharmaceutical 
applications [32–35]; however, in our knowledge, a water-soluble polyethylene glycol 
cross-linked β-CD polymer has never been tested as a drug carrier. Recently, semi-
synthetic polymeric systems based on beta and gamma cyclodextrins were produced in 
the U.K. [16–19] from renewable resources and by ‘green chemistry’ processes. The green 
chemistry concept applies throughout the entire life cycle of a chemical product, from its 
design and manufacturing to its use and final disposal [36] and relates to the chemicals, 
process and products. The properties of crystalline β-cyclodextrin have been modified by 
cross-linking in water with a family of non-toxic diepoxides having variable length of 
polyethylene glycol spacers. Two different polymeric systems with large hydrodynamic 
volumes were obtained: soluble cross-linked polymers with defined chemistry and 
chemical-physical properties and insoluble hydrogels with good physical integrity and 
important swelling power up to 200% [37,38]. The new polymeric cyclodextrin-based 
systems are promising passive and/or active ingredients for a variety of biomedical 
applications. Our concept was to test the water-soluble polyethylene glycol cross-linked 
β-CD polymer as a ‘two in one’ polymeric system, which offers a combination of β-CD 
and PEG properties. Curcumin was chosen as a model drug, which can be solubilized by 
cyclodextrins [39], cyclodextrin polymers [39] and PEG 400 [40]. 
The aim of this work was to study the complexation properties of a water-soluble 
polyethylene glycol cross-linked β-CD polymer (βCPCD) using curcumin as a model drug 
molecule and compare these properties to a water-soluble cross-linked with an 
epichlorohydrin β-CD polymer (βCDP)/curcumin system. We characterized the 
interaction of βCPCD with mucin and determined curcumin solubilization. We also aimed 
to obtain information about the role of the PEG spacer in the molecular interactions and 
reveal the complexation properties and permeability enhancement of βCPCD. Finally, a 
hard gel capsule formulation was prepared, and the dissolution profile was determined. 
2. Materials and Methods 
2.1. Materials 
The cross-linked β-cyclodextrin with polyethylene glycol diglycidyl ether (βCPCD) 
was synthetized at Cranfield University in the U.K., as previously described [17,18]. The 
soluble (2-hydroxy-3-N,N,N-trimethylamino)propyl-beta-cyclodextrin polymer 
(QAβCDP), soluble beta-cyclodextrin polymer cross-linked with epichlorohydrin (βCDP) 
were purchased from Cyclolab Ltd. (Budapest, Hungary). Curcumin, porcine gastric 
mucin (type II, Mw~640 kDa) and other reagents were obtained from Sigma-Aldrich Ltd. 
(Budapest, Hungary). 
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2.2. Phase-Solubility Test 
The phase-solubility test was performed by adding a fixed excess amount of 
curcumin powder to 2.0 mL aqueous solutions containing two different types of 
cyclodextrin polymers, βCPCD and βCDP, at increasing concentrations (0.5–10.0 m/m %). 
In the capped vials, excess amounts of curcumin powder (20.0 mg) were measured, in 
which a constant volume of purified water and increasing concentrations of each 
cyclodextrin were placed. The vials were vortexed for 30 s to achieve well-mixed 
dispersions. They were rotated at room temperature at 50 rpm and protected from light. 
After 24 h, each vial was centrifuged at 4500 rpm for 20 min. The samples were taken from 
the clear supernatant, and the curcumin content of the samples was analyzed by UV 
spectrophotometer (Shimadzu UV-1900) at 430 nm. The phase-solubility profiles of 
curcumin were achieved by plotting the solubility of curcumin versus the m/m % 
concentration of the cyclodextrin polymers. The API loading capacity was calculated by 
Equation (1). API loading capacity (‰) = Weight of dissolved APIWeight of final product × 1000 (1)
The weight of the final product was calculated from the measured mass of polymer 
and the dissolved curcumin determined by UV spectrophotometry. 
2.3. Preparation of Complexes 
Using a 10.0 m/m % polymer solution in ultrapure water prepared by Millipore 
Direct-Q 5UV system (Merck Millipore, Burlington, MA, USA), an excess amount of 
curcumin was dispersed, then stirred at 50 rpm for 24 h to reach equilibrium. The 
suspension was centrifuged at 4500 rpm for 20 min. The supernatant was frozen at −110 
°C, and the sample was lyophilized using a ScanVac CoolSafe freeze dryer (Labogene, 
Allerød, Denmark). The complexes were stored at −20 °C until used in further 
experiments. 
2.4. Dynamic Light Scattering (DLS) Measurements of Complexes 
The effect of complexation on the average particle size and particle size distribution 
of 10 m/m % solution of complexes was measured by DSL. The cyclodextrin polymer 
solutions and complex solutions were measured using a Malvern Nano-ZS Zetasizer 
(Malvern Instruments, Malvern, U.K.) in purified water. 
2.5. Solid Phase Solubilization Study 
An excess of curcumin (5.0 mg) was added to a 10% m/m % solution of polymer in 
water (3.0 mL). After stirring for 24 h, the supernatant was removed, filtered and the 
dissolved curcumin content of the clear filtered supernatant was determined by UV-VIS 
spectrophotometer (Shimadzu UV-1900) at 430 nm. Then, 1.5 mL of fresh water was 
added to the remaining solid phase and then stirred for 24 h once more. The supernatant 
was removed again, filtered and the curcumin content of the supernatant was measured 
by UV-VIS spectrophotometer. The process was repeated once more to wash twice the 
reaming solid phase. 
2.6. Nuclear Magnetic Resonance (1H and NOESY NMR) Measurements 
When the βCPCD polymer was used, 1H NMR measurements were performed on a 
Bruker Ascend 400 MHz spectrometer with a BBFO probe to examine the solid phase after 
the washing process. When curcumin was mixed with the polymer in deuterated water 
(D2O) as previously described in Section 2.4, a well-dispersed suspension was observed. 
The suspension was filtered using cotton wool and the solid was dried under high 
vacuum and re-dissolved in deuterated dimethyl sulfoxide (DMSO-d6) and the spectrum 
was recorded at ambient temperature for 16 scans. Signals representing the solvents 
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served as internal standards. The solvent peaks were referenced at 2.5 ppm (DMSO-d6) 
and 4.7 ppm (HDO, H2O). Peak multiplicities were described as follows: singlet (s), 
multiplet (m) and broad (br). 
2.7. Cytotoxicity Test 
The cytotoxic effects of the cyclodextrin polymers were evaluated using the MTT test. 
The Caco-2 cell line was obtained from the European Collection of Authenticated Cell 
Cultures (ECACC, U.K.). Cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma-Aldrich Ltd., Budapest, Hungary) supplemented with 10.0% heat-
inactivated fetal-bovine serum (Sigma-Aldrich Ltd., Budapest, Hungary), 1.0% non-
essential amino acid (Sigma-Aldrich Ltd., Budapest, Hungary) and penicillin–
streptomycin solution at 37 °C in an incubator containing 5% CO2. The passage number 
of the cells was between 37–52. The Caco-2 cell line is a colon epithelial cell line, in which 
the cells grow tightly together, forming a single cell layer. A total of 10,000 cells/well were 
seeded on 96-well plates. After 3 days, the medium was removed, and the cells were 
incubated for 30 min with the solutions of cyclodextrin polymers at 37 °C. Then, the 
samples were removed, and a 0.5 mg/mL MTT solution (3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide dissolved in phosphate buffered saline) was added to 
each well. The plates were incubated for 3 h. Then, the MTT solution was removed and 
0.1 mL isopropanol–1 M hydrochloride acid (25:1) was added to each well to dissolve the 
formed formazan crystals. The absorbance of formazan was measured at 570 nm and the 
background was measured at 690 nm by the Thermo Fisher Multiskan Go (Thermo Fisher, 
Waltham, MA, USA) microplate reader. 
2.8. In Vitro Permeability Study 
For in vitro permeability studies, Transwell® polycarbonate filters (area: 1.12 cm2, 
pore size: 0.4 µm) were used to grow Caco-2 monolayers. Studies were started after the 
initial seeding of 250,000 cells/well and the transepithelial electrical resistance (TEER) was 
monitored regularly by Millicell ERS Voltohmmeter (Millipore, USA). After TEER reached 
900 Ωcm2, the permeability tests were performed. A total of 500 µL of 6 m/m % complex 
solutions were prepared in Hanks’ Balanced Salt Solution (HBSS) and the cell monolayers 
were also washed with HBSS. The solutions of complexes were put onto the apical surface 
of cell layers. The samples were taken from the basal sides of the cell layers containing fetal 
bovine serum (FBS) at certain time points (0.5 h, 1 h and 2 h) and purified from protein by 
adding acetonitrile to the sample (1:1 ratio) and centrifuged at 12,500 rpm for 15 min. 
The samples were analyzed using an HPLC system (Merck-Hitachi ELITE with 
photodiode array detector). The column was Agilent HC-C18(2) (150 × 4.6 mm) and kept 
at 40 °C, and the detector was set at 430 nm. The mobile phase was the mixture of 
acetonitrile and 2% acetic acid solution (4:6) and a 1.0 mL flow rate was used. The analyses 
were performed with EZChrom Elite softwareTM (Hitachi, Tokyo, Japan), which was also 
used for collecting and processing data. In total, 10.0 µL standard solution and purified 
samples were injected. 
The apparent permeability coefficient (Papp) of curcumin was calculated using 
Equation (2): 𝑃 = 𝑑𝑄𝑑𝑡 × 1(𝐶 × 𝐴) (2)
where Papp is the apparent permeability coefficient (cm/s); dQ/dt is the permeability rate 
of substances (mol/s); C0 is the initial concentration of the substances in the upper 
compartment (mol/mL); and A is the surface area of the membrane (cm2). 
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2.9. In Vitro Mucoadhesive Test of Polymer 
To reveal the dominant interactions between mucin and the cyclodextrin polymers, 
dynamic light scattering (DLS) and zeta potential measurements were performed. The 
QAβCDP (positive control), βCPCD and βCDP were dissolved in pH 1.2 buffer at 10.0 
m/m % concentration. The mucin dispersion was prepared by adding mucin to deionized 
water in a concentration of 1 g L−1. The dispersion was stirred overnight, and finally 
centrifuged for 5 min at 4500 rpm. The clear supernatant was used in further experiments. 
The 1:1 ratio of cyclodextrin polymer solutions with water or mucin solution were 
prepared and the size distribution, zeta potential and mobility were measured using a 
Malvern Nano-ZS Zetasizer (Malvern Instruments, Malvern, UK). 
2.10. MicroCT Analysis 
A 10.0 m/m % solution of the polymer complexes was filled directly into 00 size hard 
gelatin capsules, which were frozen at −110 °C and lyophilized as described above. The 
formulations were kept at −20 °C until the study. The following microCT protocol was 
used to determine the formed structures. Measurements were performed with the 
SkyScan 1272 desktop micro-CT device with the following settings: image pixel size = 5 
microns; matrix size = 1344 × 2016 (rows × columns); 50 kV; 200 µA. 
2.11. Dissolution Test 
During the experiment, three parallel measurements were performed with the 00 size 
capsules prepared as described above. Each capsule contained 50 mg complexes. A total 
of 300 mL of hydrochloric acid media, pH = 1.2, without pepsin was selected for the 
dissolution tests. The rotating paddle method with the rotation speed of 75 rpm and 37 °C 
was set up in a dissolution tester (Erweka DT 800). Samples of 1.0 mL were withdrawn 
after 5 min, 15 min, 30 min and 1 h. The released amount of curcumin was determined by 
the HPLC method described above. 
2.12. Statistical Analysis 
For statistical analysis, SigmaStat (version 3.1; SPSS Inc.) and GraphPad Prism 6 
software (GraphPad Software Inc., San Diego, CA, USA) were used. Data are presented 
as means ± SD. Comparisons of two groups were performed by unpaired t-tests, while 
comparisons of more than two groups were performed using ANOVA. Differences were 
considered significant at p < 0.05. 
3. Results 
3.1. Phase-Solubility Test 
Figure 1 shows the phase-solubility curve of curcumin in the presence of increasing 
concentrations of βCDP and βCPCD. Both cyclodextrin polymers were able to improve 
the water solubility of curcumin in a cyclodextrin concentration-dependent manner. 




Figure 1. Phase-solubility curve presents the solubility of curcumin (ug/mL) in water versus the m/m 
% concentration of the cyclodextrin polymers, βCDP (green curve) and βCPCD (blue curve). Data 
are presented as means ± SD; n = 3. 
The capacity results are shown on Table 1. In solution, the βCDP has higher curcumin 
loading capacities than βCPCD. 
Table 1. Curcumin loading capacities of βCDP and βCPCD in water (data are presented as means ± 
SD; n = 3). 
Complex Capacity ‰ ± SD 
βCDP 0.332 ± 0.004 
βCPCD 0.220 ± 0.007 
3.2. Dynamic Light Scattering of Complexes 
The average sizes of polymers and the created complexes in purified water were 
measured by Malvern Nano-ZS Zetasizer and are presented on Table 2. The curcumin–
βCDP complex showed smaller size than only βCDP polymer, while the curcumin–
βCPCD complex has almost ten times higher particles than the size of the starting 
polymer. 
Table 2. The average sizes of βCDP and βCPCD and their curcumin complexes in purified water 
(data are presented as means ± SD; n = 5). 
Type of CD 
Polymer 
Size of CD Polymer ± SD (nm) Size of Curcumin Complex ± SD (nm) 
βCDP 21.1 18.4 
βCPCD 255.0 1978.0 
3.3. Solid Phase Solubilization Study 
As there was a significant difference in curcumin solubilization between the two 
polymers in the phase-solubility test with bigger aggregates observed by DLS after 
complexation with βCPCD, the solid, sedimented phase of the samples was also 
examined. The supernatant, containing the soluble complexes, was removed and the solid 
phase was washed twice with water for 24 h. After the first wash, a significantly higher 
amount of solubilized curcumin was washed out from the solid phase formed with 
βCPCD (Figure 2, left, blue box) than βCDP (Figure 2, second from left, green box). After 
the second wash, the solid phase of the βCPCD sample still contained solubilized 
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curcumin (Figure 2, center blue box), while in the case of the βCDP sample, the curcumin 
concentration in the supernatant was identical (Figure 2, second from right, green box) to 
the curcumin own solubility (Figure 2, right, purple box). As expected, the results 
confirmed that the solubility of the βCPCD polymer in water was affected by the content 
of curcumin complexed by the network. 
 
Figure 2. After incubation of excess amounts of curcumin with 10.0 m/m % βCDP and βCPCD 
solutions for 24 h, the supernatant was removed and the solid sedimented phase was further 
washed and incubated with purified water in two washing steps for 24 h in each step. The 
solubilized curcumin in the supernatant after each wash was determined and compared to the 
curcumin dissolved without cyclodextrin polymers (data are presented as means ± SD, n = 3. Labels 
of the significant differences are the following: **** p < 0.0001, ** p < 0.01, * p < 0.05). 
3.4. NMR Study 
To further investigate the composition of the solid sedimented phase of the βCPCD– 
curcumin complex discussed above, the 1H NMR spectra were examined and compared 
with those of the starting materials registered in D2O and DMSO-d6 (SI, Figures 1 and 2); 
no reference was used in the deuterated solutions as for the inclusion properties of the 
βCPCD sample. Figure 3 shows the chemical structure of βCPCD, which was soluble in 
both solvents, while curcumin floated in D2O and totally dissolved in DMSO-d6 
(Supplementary Figures S1 and S2). 




Figure 3. Proposed chemical structure of βCPCD polymer [16]. 
When curcumin was mixed with the polymer (as in Section 2.2) in D2O at room 
temperature, for 24 h, a well-dispersed yellow-orange suspension was observed to 
confirm its solubilization in water due to partial complexation in the cross-linked 
polymeric structure. After filtration of the suspension, the spectrum in DMSO-d6 of the 
insoluble βCPCD–curcumin fraction in D2O was compared with the spectrum of the 
mixture in DMSO-d6 and those of the starting materials. As expected, no changes were 
observed in the number of peaks associated to the two components, confirming that no 
chemical modification occurred upon their mixing in DMSO-d6. We note that (i) the 
solubility of the βCPCD polymer after complexation decreased in water; (ii) broader peaks 
were associated to the hydroxyl groups of the βCPCD in the regions of 6.00–4.30 ppm 
(Figure 4, purple line—curcumin, blue line—βCPCD, red line—βCPCD–curcumin 
complex fraction insoluble in D2O, black line—βCPCD–curcumin complex) were 
observed, indicating the complexation of the curcumin in the βCPCD network (Figure 4, 
OH-a and OH-b) and CD toroid (Figure 4, H-1, OH-6); and (iii) a small chemical shift of 
aromatic (7.60 ppm to 7.10 ppm) (Figure 5) and vinylic protons (6.86 ppm to 6.71 ppm) of 
curcumin (Figure 6) confirmed the interaction of the two molecules. 




Figure 4. Comparison of 1H NMR spectra in DMSO-d6 of curcumin (purple), βCPCD (blue), 
insoluble fraction in D2O of βCPCD–curcumin mixture (red) and βCPCD–curcumin mixture (black) 
at 6.00–4.30 ppm. 
 
Figure 5. Comparison of 1H NMR spectra, in DMSO-d6 of curcumin (purple), βCPCD (blue), 
insoluble fraction in D2O of βCPCD–curcumin mixture (red) and βCPCD–curcumin mixture (black) 
at 7.60–7.10 ppm. 




Figure 6. Comparison of 1H NMR spectra, in DMSO-d6 of curcumin (purple), βCPCD (blue), 
insoluble fraction in D2O of βCPCD–curcumin mixture (red) and βCPCD–curcumin mixture (black) 
at 6.86–6.71 ppm. 
Additionally, preliminary two-dimensional (2D) NOESY NMR analysis of the 
βCPCD–curcumin complex in DMSO-d6 provided further evidence of the spatial 
relationships among the protons of βCPCD within the complex when the curcumin guest 
molecule is placed inside the 3D structure of the cross-linked polymer. Figure 7 reports 
the 2D NMR NOESY spectra of the βCPCD and βCPCD–curcumin complex in DMSO-d6. 
The intramolecular cross peaks centered at 5.70 ppm (Figure 7, H-1 anomeric protons) and 
4.80 ppm (Figure 7, OH-a, OH-b and OH-6) indicated that the curcumin takes on the 
motional properties of the βCPCD while bound. Further characterization of the βCPCD–
curcumin complex formation by using two-dimensional NMR spectroscopy and scanning 
electronic microscopy is under investigation. 
 




Figure 7. Comparison of 2D NMR NOESY spectra of βCPCD (A) and βCPCD–curcumin mixture (B) 
in DMSO-d6 at 6.00–2.80 ppm. 
3.5. Cytotoxicity Test 
Figure 8 shows that cyclodextrin polymers were not cytotoxic on Caco-2 cells after 30 
min of incubation up to 5.0 m/m % concentration, but at 10.0 m/m %, the cell viability 
decreased significantly compared to the untreated control (p < 0.05, n = 5). 
 
Figure 8. Cytotoxicity of βCDP and βCPCD measured by MTT test on Caco-2 cells after 30 min 
incubation at 37 °C (data are presented as means ± SD; n = 5). 
3.6. In Vitro Permeability Study 
The permeability of curcumin using cyclodextrin polymer complexes of 6.0 m/m % 
were tested on Caco-2 monolayers. Both polymers were able to significantly improve (p < 
0.005) the curcumin permeation. The Papp value of curcumin, 1.23 × 10−6 cm/s, was 
increased to 5.70 × 10–6 cm/s and 22.40 × 10−6 cm/s by the βCDP and βCPCD complexes, 
respectively (Figure 9). 




Figure 9. Permeability of curcumin on Caco-2 monolayers treated with curcumin–cyclodextrin 
complexes. Cyclodextrin polymers significantly increased Papp of curcumin (data are presented as 
means ± SD, p < 0.0005, n = 3) (Papp—apparent permeability coefficient). 
TEER values of the Caco-2 monolayers were measured before and after the 
permeability test. No significant decreases in TEER values were observed after the in vitro 
permeability study, indicating that the integrity of the monolayers was not damaged. 
3.7. In Vitro Mucoadhesive Test of Polymers 
The in vitro mucoadhesive test result is summarized in Table 3. Mucin had an 
average size of 391.0 ± 7.2 nm with negative zeta potential. A positively charged 
cyclodextrin polymer, QAβCDP, was used as a positive control, which had positive zeta 
potential value. In the case of QAβCDP and mucin mixture, we detected increased particle 
size and increased zeta potential. The βCDP had also a negative charge with a similar size 
to QABCDP. The size of the βCDP–mucin particles doubled, compared to mucin, while 
the zeta potential did not increase significantly. The βCPCD polymer showed the highest 
size increase after the interaction with mucin with the particle diameter of 2052.0 ± 120.9 
nm; however, there was no significant change in the zeta potential. 
Table 3. Interaction of mucin with different cyclodextrin polymers measured by DLS and zeta 
potential (data are presented as means ± SD, n = 5). 
Sample Name Size ± SD (nm) Zeta Potential ± SD (mV) Mobility ± SD (µm cm/s) 
Mucin 391.0 ± 7.2 −3.12 ± 0.36 −0.2445 ± 0.0276 
QAβCDP 9.3 ± 0.2 2.28 ± 0.65 0.1785 ± 0.0508 
QAβCDP + Mucin 1326.0 ± 89.7 −0.77 ± 0.65 −0.0603 ± 0.0976 
βCDP 11.9 ± 0.2 −2.02 ± 0.16 −0.1584 ± 0.0126 
βCDP + Mucin 803.0 ± 22.0 −2.34 ± 0.22 −0.1835 ± 0.0170 
βCPCD 33.1 ± 0.2 0.08 ± 7.07 × 10−5 0.006 ± 7.7800 ×10−6 
βCPCD + Mucin 2052.0 ± 120.9 −2.40 ± 0.27 −0.1877 ± 0.0213 
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3.8. MicroCT Analysis 
The images of microCT scans performed on curcumin–cyclodextrin polymer 
complexes formulated into hard gelatin capsules are presented in Figure 10. The capsule 
formulations were prepared by lyophilization, and the complexes showed different 
structures after removal of the solvent. The cyclodextrin polymer complex formed by 
βCPCD showed a highly porous structure with filaments (Figure 10a); in contrast, the 




Figure 10. The microCT images of capsules filled with curcumin–βCPCD complex (a) and curcumin–βCDP complex (b) 
after lyophilization. 
3.9. Dissolution Test 
The capsules filled with the two types of complexes were tested by dissolution tests. 
During dissolution, complete drug release was observed within 1 h in both cases. In the 
case of the curcumin–βCDP complex, the total capsule dissolution occurred after 15 min, 
while in the case of the curcumin–βCPCD complex, the dissolution finished after 30 min. 
In the case of the curcumin–βCDP complex, complete dissolution occurred after 
disintegration, while in the second case, the disintegration and the release of the active 
ingredient into solution took place simultaneously (Figure 11). 
 
Figure 11. Dissolution curves of hard gelatin capsules filled with curcumin–cyclodextrin polymer 
complexes (data are presented as means ± SD; n = 3). 




A new ‘two in one’ water-soluble β-cyclodextrin polymer (βCPCD) was synthetized 
recently based on cyclodextrins covalently cross-linked with diepoxides having polyethylene 
glycol (PEG) spacers [18]. Both polyethylene glycol and β-cyclodextrin are widely used in 
pharmaceutical formulations, but their covalent bond polymeric combination has not yet 
been tested for complexation and drug delivery. Curcumin a water-insoluble drug was 
used as a model drug, to test the complexation properties of water-soluble βCPCD, and 
compared to those of the water-soluble βCDP. The two polymers differ in their cross-
linkers, as βCDP cross-linked with epichlorohydrin; thus, differences in their physical and 
drug complexing properties were expected. In general, PEG chains can be hydrated, 
causing larger hydrodynamic radius of the polymer molecules. This was reflected in the 
DLS results, where βCPCD showed a larger size in two different experiments at two 
different pH values compared to βCDP. It is especially interesting to associate their 
molecular weights to the DLS data, as βCPCD is less than 5 kDa calculated from GPC 
experiments using the PEG/PEO standards, while βCDP is around 105 kDa determined 
by the static light scattering method referred by the manufacturer. The two methods are 
not identical, but the dynamic light scattering test results indicate that βCPCD can be 
hydrated with water at a much higher extent, causing a larger hydrodynamic radius. The 
other property of βCPCD is the mucoadhesion. The interaction of mucin and the polymers 
was tested in solution at pH 1.2 by DLS. As a positive control, the positively charged 
QAβCDP was used. It is well known that mucin has a negative charge, which ensures the 
attachment of positively charged particles and polymer chains on its surface, and on the 
other hand, mucin also has the ability to form gel and adhere polymers. In the case of the 
QAβCD and mucin mixture, we detected interconnected, significantly larger colloidal 
molecules whose zeta potential was increased compared to mucin. Like mucin, βCDP also 
had negative charges, but the polymer structure gave an opportunity for association. The 
formed mucin–βCDP particle size is doubled, while the zeta potential did not increase 
significantly. The βCPCD polymer was cross-linked with PEG, with presumed 
mucoadhesive properties. Indeed, the highest size increase was observed with βCPCD, 
even if the zeta potential showed just a minor change compared to mucin. Interestingly, 
PEG was reported earlier to be non-mucoadhesive [41], but it can enhance the 
mucoadhesion of other polymers such as poly(2-hydroxyethyl methacrylate) [42]. Mucins 
contain numerous hydrogen-bonding active groups and this is the molecular basis of the 
primary interaction for mucins [43]. It seems that PEG increases the interaction of βCPCD 
with mucin by hydrogen bonding, causing the enhanced aggregation of βCPCD and 
mucin compared to βCDP and QAβCD. PEG seems to be more effective to increase 
mucoadhesion than epichlorohydrin cross-linker, which can contribute to the enhanced 
drug penetration, but this relationship should be confirmed. 
Phase-solubility experiments showed that βCDP solubilized curcumin more 
effectively than βCPCD; however, the size of the complex particles showed an interesting 
phenomenon. The particle size of the βCPCD–curcumin complex was almost eight times 
bigger than βCDP. This indicates the formation of an aggregated structure with a possibly 
lower solubility in water. In general, the complexation ability of the cyclodextrin polymers 
can be explained by their 3D conformation in water; they have two different regions where 
the curcumin can be housed, (i) the toroid structure of CD or (ii) the network formed by 
the cross-linkers in the polymers. However, PEG chains in βCPCD enhance the 
complexation ability by the formed 3D network with its more flexible structure (Figure 
12). 




Figure 12. Schematic representation of βCPCD–curcumin complex. The yellow-colored curcumin 
molecules are entrapped in the β-CD cavity and in the 3D cross-linked area. 
A possible explanation for the solubility differences between the two polymers could 
be that due to the precipitation of the βCPCD–curcumin complex into the sedimented 
solid phase, the curcumin concentration in the supernatant solution decreased. To confirm 
this hypothesis, the solid phase was washed, and we found that the βCPCD–curcumin 
complex could be further dissolved from the sediment. The presence of the βCPCD–
curcumin complex in the sediment was proved by NMR. According to these results, the 
solubility of both the guest and the host components is affected upon mixing. The 
curcumin is trapped in the βCPCD polymeric network while the solubility of the polymer 
is decreased. Interestingly, this could not be concluded from the shape of the phase-
solubility diagram, as it was also linear in the case of βCPCD. A possible explanation could 
be that the applied host molecule was a polymer, which contains molecules with different 
molecular weights and with different solubility upon complexation. Applying different 
concentrations in the phase-solubility test, the molecular fraction with less solubility 
precipitated proportionally, resulting in a linear phase-solubility curve. This hypothesis 
should be further investigated. Of note, the loading capacity of the polymers was low. 
This can be partially explained by the way of calculation of the loading capacity of the 
polymer; due to their high molecular weight, large amounts of polymers should be used 
to obtain a suitable molar ratio for complexation, which reflects in the smaller value of the 
loading capacity. The loading capacity could be improved by using other complexation 
methods and βCPCD kneading could be an alternative method; however, this theory 
should be confirmed experimentally. Curcumin was used as a model drug in the 
experiments. Indeed, the formulated dose is small compared to the therapeutically 
applied doses, but βCPCD increased its permeability twenty times. Due to this positive 
effect of the polymer on bioavailability of curcumin, the orally applied dose could be 
reduced. More potent drugs with small doses (< 1mg) would be more suitable to form 
therapeutically relevant new drug formulations. 
In the cytotoxicity test, both polymers showed toxic properties only at higher 
concentrations (10.0 m/m %); however, more than 80% of the cells remained viable after 30 
min of incubation. TEER measurements were carried out before and after the permeability 
tests to confirm that cyclodextrin polymer complexes did not induce cell toxicity or the 
disruption of the monolayer’s integrity during the 2 h of permeability test. TEER values 
did not decrease significantly after the in vitro permeability studies, showing that the 
functionality and the integrity of the monolayers were not damaged by cyclodextrin 
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polymers at the applied 6.0 m/m %. βCPCD improved the curcumin permeability to a 
significantly higher extent than βCDP, which can be explained by its stronger 
mucoadhesion and improved contact with the surface of the cell layer. Indeed, the larger 
hydrodynamic radius creates a larger surface of the complex particles, improving the 
diffusion of curcumin from the complex into the cell layer. On the other hand, βCPCD can 
more efficiently deliver the complexed curcumin to the cell membrane, and possibly, the 
hydrated PEG chains may easier pass through the unstirred water layer on the surface of 
the cell layer. 
Finally, the structure analysis of the formed capsules demonstrated that βCPCD 
forms a filament-like structure after lyophilization, which swelled during dissolution due 
to the PEG cross-linker. Nevertheless, the dissolution of both formulations was fast—
within 1 h, complete curcumin release was observed. 
5. Conclusions 
In conclusion, the new ‘two in one’ PEG–βCD polymer was applied for the first time 
successfully to the complexation and formulation of curcumin. The PEG chains provide 
the cyclodextrin-based polymer with some beneficial properties, including mucoadhesion 
and complexation. Both PEG and βCD are widely applied pharmaceutical excipients, and 
thus, the new PEG–βCD system formed through covalent cross-linking could be 
considered as a new alternative for the formulation of matrix systems for poorly soluble 
drugs. 
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